Altimmune, Inc. — Director's Dealing 2012

Dec 6, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2012-12-03

Reporting Person: Karp Jordan P (SVP, General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-03	Stock Options (right to buy)	$1.13	A	65000	Acquired	2022-12-03	Common Stock (65000)	Direct

Footnotes

F1: The options vest over a 4 year period with 25% each vesting on the first, second, third and fourth anniversaries of the grant date.

F2: On December 3, 2012, the date such options were granted, the closing price of the Issuer's Common Stock on the NYSE Amex was $1.13 per share.